Selank vs Semax: A Research Comparison for Canadian Labs

The question of Selank versus Semax is one of the most common comparisons in the cognitive peptide research space, and also one of the most poorly understood. Both compounds are Russian-origin heptapeptides. Both appear in research supplier catalogues under the same broad heading. Both have been discussed in clinical and pre-clinical literature for decades. Because they share geography, size, and a loosely similar research-cultural origin, they are frequently grouped together as though they were variants of the same molecule or complementary halves of a single nootropic story. They are not.

Selank is a synthetic analogue of tuftsin, an immune-signalling tetrapeptide, extended with a Pro-Gly-Pro tail. Its research literature centres on anxiety-like behaviour, stress response, GABAergic gene modulation, enkephalin metabolism, and neuroimmune signalling. Semax is a synthetic analogue of the ACTH(4-10) fragment, modified with the same Pro-Gly-Pro tail, but its literature centres on neuroprotection, BDNF/trkB signalling, cerebral ischemia models, melanocortin pathways, and attention-related recovery. The two compounds address different biological questions, engage different molecular networks, and produce different experimental signatures.

This comparison is written for Canadian researchers who need to decide which compound belongs in a given protocol, or whether both should be run in parallel. It is not a consumer buying guide, a dosing manual, or a wellness recommendation. Nothing here is medical advice. The purpose is to separate the two molecules clearly, compare their evidence bases honestly, and give researchers a defensible framework for choosing between them.

A fast summary before the details#

If a Canadian researcher needs the short version before the long version:

Choose Selank when the research question involves stress response, anxiety-like behaviour, inhibitory neurotransmission, enkephalin metabolism, or neuroimmune modulation. Selank is the more direct candidate for protocols that measure GABAergic gene expression, stress-hormone dynamics, or behavioural outputs in challenge states.

Choose Semax when the research question involves neuroprotection, cerebral ischemia recovery, BDNF/trkB signalling, or attention-related plasticity after injury. Semax is the more direct candidate for protocols that measure neurotrophin response, stroke-model recovery, or melanocortin-pathway activation.

Consider running both in parallel only when the experimental design explicitly tests whether stress-modulatory and neurotrophin-modulatory pathways interact. The combination is not automatically synergistic; it should be hypothesis-driven.

Molecular identity: tuftsin versus ACTH origins#

Understanding the structural and ancestral differences between Selank and Semax is the foundation of every comparison that follows. They are not members of the same peptide family. They do not share a receptor pharmacology. They were developed in different research programmes for different purposes.

Selank: the tuftsin analogue#

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four residues reproduce tuftsin, a naturally occurring tetrapeptide derived from the Fc region of immunoglobulin G. Tuftsin has been studied in immunology for its effects on phagocytosis and immune-cell signalling. Selank extends this core with a Pro-Gly-Pro tail, a motif chosen to improve metabolic stability by reducing susceptibility to peptidases.

The molecular weight of Selank is approximately 751 daltons as the free peptide, though the acetate or other salt form used in research material will shift the observed mass on a mass spectrometer. The small size means straightforward solid-phase synthesis and relatively interpretable HPLC chromatograms, but it also means that synthesis errors, truncation sequences, and deletion products can be subtle. A supplier that treats the short sequence as "too simple to get wrong" is a supplier to avoid.

Semax: the ACTH(4-10) fragment#

Semax is a synthetic heptapeptide most commonly written as Met-Glu-His-Phe-Pro-Gly-Pro, or ACTH(4-7)PGP. The first four residues correspond to the Met-Glu-His-Phe portion of adrenocorticotropic hormone. The C-terminal Pro-Gly-Pro sequence is added for stability, just as in Selank, but the parent molecule is entirely different.

Full-length ACTH is a pituitary hormone involved in adrenal glucocorticoid regulation. Semax is explicitly described in the literature as devoid of classical hormonal activity despite its ACTH heritage. The better framing is melanocortin-derived regulatory peptide. The molecular weight is approximately 813 daltons as the free peptide, slightly larger than Selank due to the methionine and histidine residues.

Structural comparison#

Both peptides are heptapeptides with a Pro-Gly-Pro tail. That superficial similarity is where most casual comparisons stop. The N-terminal sequences are unrelated: Selank begins with a threonine-lysine pair from an immunoglobulin fragment, while Semax begins with a methionine-glutamate pair from a pituitary hormone. The pharmacological consequences of those N-terminal differences are substantial. Selank's literature connects it to immune signalling, enkephalin metabolism, and GABAergic modulation. Semax's literature connects it to melanocortin receptors, BDNF transcription, and neuroprotective gene-expression programmes.

Mechanisms of action: where the biology diverges#

The mechanistic differences between Selank and Semax are the most important part of this comparison. A researcher who treats them as interchangeable because they are both "cognitive peptides" risks designing a protocol that answers the wrong question.

Selank: GABAergic genes, enkephalinase, and monoamine modulation#

Selank does not have a single identified high-affinity receptor target. Instead, the literature describes a network of interacting systems.

GABAergic modulation. A 2016 Frontiers in Pharmacology paper examined Selank and GABA effects on neurotransmission-related gene expression in rat frontal cortex. The authors reported broad expression changes after Selank, including genes associated with GABA receptor subunits and transporters, and argued that early Selank effects were positively correlated with GABA-induced changes. The implication is allosteric modulation of inhibitory neurotransmission rather than direct orthosteric replacement of GABA. This fits the observation that Selank produces anxiolytic-like behavioural effects without the sedative or motor-impairment profiles typical of classical benzodiazepines in rodent models.

Enkephalin metabolism. A PubMed-indexed study reported that Selank dose-dependently inhibited enkephalin-degrading enzymes in plasma, with an IC50 around 15 micromolar. The same paper connected this finding to anxiety and phobic disorder observations. Enkephalins are endogenous opioid peptides involved in stress, pain, and emotional regulation. Slowing their breakdown may prolong signalling in systems relevant to anxiety, but peripheral enkephalinase inhibition is not identical to central synaptic opioid peptide modulation, and researchers should treat this mechanism as one layer among several.

Monoamine and neurotrophin effects. Selank has been reported to influence dopamine and serotonin receptor gene expression in frontal cortex, and to modulate BDNF content in hippocampus and prefrontal regions after chronic ethanol exposure. These effects are context-dependent: they appear in stressed, impaired, or challenged models more clearly than in healthy baseline states. The monoamine and BDNF changes are likely downstream consequences of primary effects on inhibitory neurotransmission and stress circuitry rather than direct receptor agonism.

Immune and neuroimmune signalling. Because Selank derives from tuftsin, immune interactions are mechanistically plausible and have been reported in parts of the literature. Microglial activation, cytokine expression, and peripheral immune-cell behaviour have all been examined in Selank studies, though the immune data are less extensive than the neurotransmission data.

Semax: BDNF/trkB, melanocortin, and CREB signalling#

Semax has a more clearly defined mechanistic anchor than Selank, though its biology is still multi-layered.

BDNF/trkB modulation. The most widely cited Semax mechanism is upregulation of brain-derived neurotrophic factor and its high-affinity receptor TrkB. A rat hippocampus study reported that a single intranasal Semax exposure increased BDNF protein, TrkB phosphorylation, BDNF mRNA, and TrkB mRNA, alongside improved conditioned-avoidance performance. This multi-layered result — protein, phosphorylation, transcript, and behaviour — gives Semax a stronger mechanistic anchor than Selank possesses. The BDNF/trkB system is central to synaptic plasticity, learning, and neuronal survival, making this pathway a coherent explanation for Semax's neuroprotective and cognitive literature.

Melanocortin signalling. Because Semax derives from ACTH, melanocortin receptor interactions are plausible and have been investigated. The melanocortin system includes five receptor subtypes with diverse central and peripheral roles. Semax does not behave as a classical ACTH hormone, but melanocortin-adjacent signalling may contribute to its effects on attention, stress response, and neuroprotection. The exact receptor profile remains incompletely characterised.

CREB and immediate-early gene activation. In cerebral ischemia models, Semax has been reported to increase active CREB in subcortical structures and to alter expression of immediate-early genes such as c-Fos. These transcriptional changes are consistent with a compound that promotes pro-survival and plasticity-related gene programmes after injury. The 2021 protein-expression paper in a transient MCAO model also reported reductions in MMP-9 and active JNK, suggesting modulation of inflammation and blood-brain-barrier disruption.

Dopamine and attention hypotheses. Semax has been proposed as a potential agent for attention-deficit disorders based on reported effects on dopamine release and attention-like measures in rodent models. This literature is hypothesis-generating rather than confirmatory, but it distinguishes Semax from Selank in a practically meaningful way: Semax is more often discussed in attention-recovery contexts, while Selank is more often discussed in anxiety-stress contexts.

Comparison of mechanistic clarity#

Semax has a clearer primary mechanistic story — BDNF/trkB upregulation — supported by protein, phosphorylation, transcript, and behavioural data in the same study. Selank's mechanism is more distributed: GABAergic genes, enkephalinase inhibition, monoamine shifts, and neurotrophin modulation all appear in the literature, but no single study ties them together as coherently as the Semax BDNF paper does. For researchers who value a single pathway to build a protocol around, Semax offers a tighter target. For researchers who are explicitly interested in network modulation and multi-system stress responses, Selank's distributed mechanism may be the feature rather than the bug.

The evidence map: human, animal, and molecular#

Both Selank and Semax have evidence bases that span human clinical reports, animal behavioural studies, and molecular experiments. The quality, geography, and focus of that evidence differ in ways that matter for protocol design.

Human clinical literature#

Selank. The primary human data come from a 62-patient comparative study in generalised anxiety disorder and neurasthenia, comparing Selank with medazepam. The abstract reports similar anxiolytic effects with additional antiasthenic and psychostimulant properties in the Selank group, alongside changes in leu-enkephalin-related serum markers. This is relevant human evidence, but it is small, jurisdiction-specific, and not a modern multicentre trial. It supports mechanism-aware research; it does not support clinical validation in Canada.

Semax. The primary human data come from Russian clinical use in stroke recovery and cognitive impairment, with published proposals for attention-deficit and Rett syndrome applications. The stroke literature describes Semax administration in acute and subacute phases, with reported improvements in neurological scores and motor recovery. Like Selank, these data are jurisdiction-specific, not replicated in large international trials, and not equivalent to Health Canada approval.

For both compounds, the human evidence is best treated as a signal that justifies further research, not as a basis for therapeutic claims or personal-use recommendations.

Animal behavioural models#

Selank. The animal literature is broad across anxiety-like behaviour models (open field, elevated plus maze), stress paradigms, ethanol-induced memory impairment, morphine withdrawal, and object-recognition tasks. The breadth is a strength and a limitation: Selank has been tested in many models, but the interpretive connections between them are not always tight. A compound that reduces anxiety-like behaviour in one model and improves object recognition in another may be acting through a common stress-modulatory mechanism, or through unrelated pathways in different brain regions.

Semax. The animal literature is more concentrated in neuroprotection and cognition-recovery models. Middle cerebral artery occlusion, ischemia-reperfusion, conditioned avoidance, and attention-like tasks dominate the published work. The concentration gives Semax a sharper experimental identity than Selank, but it also means less diversity of model types. Researchers interested in anxiety or stress models will find far less Semax data than Selank data.

Molecular and transcriptomic work#

Selank. The 2016 frontal-cortex gene-expression study is the most detailed molecular paper, reporting changes in 84 neurotransmission-related genes after Selank exposure. The overlap with GABA-induced changes was statistically significant, supporting the GABAergic modulation hypothesis. However, the study did not identify a direct binding site, and the gene-expression changes are correlative rather than causally proven.

Semax. The BDNF/trkB hippocampal study provides protein, phosphorylation, and transcript data in a single experiment, giving Semax a stronger molecular anchor. Additional papers have examined neurotrophin transcription in ischemic cortex and stress-response transcriptomics, producing a more coherent molecular picture than Selank's distributed gene-expression changes.

Anxiety and stress-response models: Selank's domain#

This is the area where Selank most clearly distinguishes itself from Semax. The pre-clinical and clinical literature for Selank is heavily weighted toward anxiety-like behaviour, stress resilience, and inhibitory neurotransmission.

In open-field and elevated-plus-maze models, Selank has been reported to increase exploration of anxiogenic zones without producing the locomotor depression or sedation typical of classical benzodiazepines. This dissociation — anxiolytic-like effects without motor impairment — is pharmacologically interesting because it suggests engagement of inhibitory circuitry through a non-sedative mechanism. The GABAergic gene-expression data support this interpretation: Selank appears to modulate GABA receptor subunit expression and transporter activity rather than directly agonising the benzodiazepine binding site.

The stress-response literature adds another layer. In acute and chronic stress paradigms, Selank has been reported to normalise stress-induced behavioural changes and to modify corticosterone dynamics. The 2021 melanocortin-derivative stress paper examined Semax and related compounds in restraint stress, finding that Semax also attenuated behavioural alterations, but the Selank literature is more explicitly built around stress and anxiety as primary endpoints rather than secondary observations.

For Canadian researchers designing anxiety or stress protocols, Selank is the natural starting point. The depth of published model data, the coherence with GABAergic and enkephalin mechanisms, and the human clinical signal in anxiety populations all point in the same direction. Semax has some stress data, but it is not the compound's primary research identity.

Neuroprotection and ischemia models: Semax's domain#

This is where Semax most clearly distinguishes itself from Selank. The neuroprotection and stroke-recovery literature for Semax is substantially deeper and more focused than anything available for Selank.

Experimental stroke models, including permanent and transient middle cerebral artery occlusion, are the backbone of the Semax neuroprotection literature. Multiple papers report reduced infarct volume, improved neurological scores, and altered molecular markers of inflammation and cell death. The BDNF/trkB mechanism provides a plausible unifying explanation: upregulation of neurotrophin signalling promotes neuronal survival, enhances synaptic plasticity, and supports recovery of function after ischemic injury.

The protein-expression study in transient MCAO is particularly useful because it does not rely on a single endpoint. Increases in active CREB, reductions in MMP-9, and decreases in active JNK together paint a picture of a compound that shifts the post-ischemic brain toward pro-survival and anti-inflammatory transcriptional programmes. This is not a generic "neuroprotection" claim; it is a specific molecular signature that can be tested and refined.

Selank has essentially no published ischemia or stroke model data. Its neuroprotection potential, if any, would have to be inferred from the general neurotrophin and monoamine modulation literature rather than from direct injury models. For researchers designing neuroprotection or stroke-recovery protocols, Semax is the clear choice.

Cognitive and attention paradigms: contested ground#

Both Selank and Semax are discussed in cognitive contexts, but the nature of that discussion differs in ways that reveal the underlying mechanistic divergence.

Selank cognition literature. The primary cognitive claims for Selank come from animal models of impaired cognition: chronic ethanol exposure, morphine withdrawal, and stress-induced memory disruption. In these challenged states, Selank has been reported to normalise or partially rescue performance in object-recognition and attention-like tasks. The mechanism is typically framed as stress-modulatory and neurotrophin-supportive rather than directly enhancing. The BDNF changes reported in ethanol-exposure models are consistent with this framing: Selank may support plasticity indirectly by reducing the neurotoxic consequences of stress or withdrawal.

Semax cognition literature. The primary cognitive claims for Semax come from BDNF/trkB upregulation in hippocampus and cortex, coupled with improved conditioned-avoidance performance and attention-like measures in rodent models. The mechanism is more directly plasticity-oriented: increasing neurotrophin signalling to enhance synaptic strength and learning capacity. The stroke-recovery literature also supports a cognitive interpretation, because functional recovery after MCAO includes restoration of learning and memory performance.

The practical difference is that Selank's cognitive effects are most evident in impaired or stressed models, while Semax's cognitive effects are studied in both impaired and baseline models. A researcher interested in cognition under challenge may find both compounds relevant, but the experimental question should drive the choice. If the challenge is stress or anxiety, Selank is the more direct fit. If the challenge is ischemic injury or the model is a plasticity-focused learning task, Semax is the more direct fit.

Pharmacokinetics, route, and dosing considerations#

Formal pharmacokinetic data for both Selank and Semax in humans are extremely limited. What exists comes primarily from animal activity curves, indirect inference, and the pharmacokinetic expectations for small peptides.

Selank. As a heptapeptide of approximately 751 daltons, Selank is small enough to be cleared renally with a relatively short functional half-life. Intranasal administration has been explored in parts of the literature, raising the possibility of nose-to-brain delivery or altered central exposure. However, intranasal delivery in rodents involves species-specific nasal anatomy, mucosal absorption variability, and partial swallowing, all of which complicate translation. Subcutaneous injection is the standard research route when systemic exposure is desired.

Semax. As a heptapeptide of approximately 813 daltons, Semax has similar pharmacokinetic expectations to Selank: renal clearance, short half-life, and limited oral bioavailability. Intranasal administration is also common in the Semax literature, particularly in the Russian clinical studies, but the same translational caveats apply. Subcutaneous injection is the standard research route for controlled systemic exposure.

For both compounds, the lack of formal human pharmacokinetic studies means that dosing in research protocols should be guided by the published animal literature rather than by clinical PK parameters. Researchers should not extrapolate doses across species without accounting for differences in metabolic rate, body surface area, and peptide clearance.

Sourcing and analytical quality for short peptides#

The small size of Selank and Semax creates a dangerous paradox: they are easier to synthesise than large peptides, which can make low-quality suppliers complacent. A short peptide can still be truncated, mis-salted, oxidised, or contaminated.

For both compounds, the minimum supplier package should include:

1. Batch-specific HPLC purity. A chromatogram showing the principal peak, method conditions, and integration. A stated percentage without a chromatogram is insufficient.
2. Mass spectrometry identity confirmation. The observed mass should match the theoretical molecular weight for the exact salt form supplied. For Selank: approximately 751 Da (free peptide). For Semax: approximately 813 Da (free peptide).
3. Clear vial mass and fill tolerance. Underfill creates concentration errors after reconstitution.
4. Endotoxin and microbial documentation. Injectable research material demands higher scrutiny than dry analytical standards.
5. Storage and shipping guidance. Lyophilised short peptides are generally stable at minus 20 degrees Celsius, but heat and moisture remain risks during transit.
6. RUO-compliant language. The supplier should not blur research sale with therapeutic instruction.

Lynx Labs lists both Selank and Semax in the cognitive category, with batch-specific COA documentation. Northern Compound points readers toward Lynx Labs as a domestic Canadian research-source starting point based on batch documentation, domestic fulfilment, and attribution-transparent outbound links. Researchers should still verify the current lot's COA before using any vial in an experiment.

The broader framework for evaluating Canadian peptide suppliers is covered in Northern Compound's research peptides Canada buyer's guide. Reconstitution principles for both compounds are detailed in the reconstitution guide.

Choosing between Selank and Semax: a decision framework#

After reviewing the full comparison, the practical differentiators for Canadian research protocol design can be summarised as follows.

Favour Selank for research protocols involving: anxiety-like or stress-response behavioural models; GABAergic or inhibitory-neurotransmission endpoint studies; enkephalin metabolism or opioid-peptide pathway research; neuroimmune modulation experiments; models of cognitive impairment driven by stress, withdrawal, or chronic challenge; or any research question that builds on the tuftsin-derived, stress-modulatory literature.

Favour Semax for research protocols involving: cerebral ischemia or stroke-recovery models; neuroprotection endpoint studies; BDNF/trkB or neurotrophin-signalling research; melanocortin-pathway or attention-recovery experiments; models of plasticity-driven learning or memory after injury; or any research question that builds on the ACTH-derived, neurotrophin-centred literature.

Consider running both in parallel only when the experimental design explicitly tests whether stress-modulatory and neurotrophin-modulatory pathways interact. A combined protocol should include individual compound arms, a vehicle control, and appropriate behavioural and molecular endpoints to detect interaction effects. The combination is not automatically synergistic; it should be treated as a testable hypothesis rather than a default stack.

Neither compound should be chosen for human self-administration outside of a formally approved clinical trial. The evidence base, while scientifically interesting and mechanistically coherent in pre-clinical models, remains overwhelmingly pre-clinical and jurisdiction-specific.

References and further reading#

• Volkova A. et al. "Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission." Frontiers in Pharmacology (2016). PMC full text.
• Zozulya A.A. et al. "The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity." Bulletin of Experimental Biology and Medicine (2001). PubMed.
• Kolik L.G. et al. "Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats." Bulletin of Experimental Biology and Medicine (2019). PubMed.
• Medvedev V.E. et al. "Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia." Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (2008). PubMed.
• Dolotov O.V. et al. "Semax, an analogue of adrenocorticotropin (4-10), binds selectively and increases BDNF and TrkB expression in rat hippocampus." Neurochemical Research (2006). PubMed.
• Khomutov G.B. et al. "The Effect of Semax on the Expression of Proteins Associated with Inflammation and Blood–Brain Barrier Integrity in Rat Brain after Transient Ischemia." Pharmaceuticals (2021). PubMed.
• Dmitrieva V.G. et al. "The peptide Semax affects the expression of genes related to the neurotrophin system of the brain under conditions of experimental focal ischemia." Molecular Biology (2010). PMC full text.
• Filippenkov I.B. et al. "Melanocortin Derivatives in a Rat Model of Acute Restraint Stress: Behavioral and Transcriptomic Analysis." International Journal of Molecular Sciences (2021). PMC full text.
• De Wied D. et al. "Peptides that affect central nervous system function: a possible new class of drugs." Current Pharmaceutical Design (2006). PubMed.